TriangleNCT00321464 · CITED IN SOURCE DOCUMENTS
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2022-11-08
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Adults with histologically or cytologically confirmed breast adenocarcinoma * radiographic evidence of at least one bone mets * Easter Cooperative Oncology Group status of 0, 1 or 2; * adequate organ function Exclusion Criteria: * Current or prior IV bisphosphonate administration * current or prior oral bisphosphonates for bone mets * life expectancy of less than 6 months
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: Zoledronic Acid
- label
- zoledronic acid
- type
- ACTIVE_COMPARATOR
- intervention Names
- Biological: Denosumab
- label
- denosumab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- denosumab
- description
- Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
- name
- Denosumab
- type
- BIOLOGICAL
- arm Group Labels
- zoledronic acid
- description
- Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
- name
- Zoledronic Acid
- other Names
- Zometa
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- TRIPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- primary Purpose
- SUPPORTIVE_CARE
Enrollment
- count
- 2049
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
- measure
- Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)
- time Frame
- Up to 34 months
- secondary Outcomes
- description
- Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
- measure
- Time to First On-Study Skeletal-Related Event (Superiority)
- time Frame
- Up to 34 months
- description
- Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.
- measure
- Time to First and Subsequent On-Study Skeletal-Related Event
- time Frame
- Up to 34 months
Full study description
- brief Summary
- The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
Source references
- references
- citation
- Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5.
- pmid
- 22951813
- type
- BACKGROUND
- citation
- Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012 Sep 1;18(17):4841-9. doi: 10.1158/1078-0432.CCR-11-3310. Epub 2012 Aug 14.
- pmid
- 22893628
- type
- BACKGROUND
- citation
- Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.
- pmid
- 21060033
- type
- BACKGROUND
- citation
- Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3.
- pmid
- 26335402
- type
- DERIVED
- citation
- Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.
- pmid
- 26093811
- type
- DERIVED
- citation
- Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.
- pmid
- 25976743
- type
- DERIVED
- citation
- von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.
- pmid
- 23975226
- type
- DERIVED
- citation
- Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.
- pmid
- 22975218
- type
- DERIVED
- see Also Links
- label
- AmgenTrials clinical trials website
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-2d2f0b8ac88a9811d19a
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- 5959022d-c2d4-11ec-e063-6294a90a6cd6
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 3eeb394daedeec8fd66096a97d469a15bb806ccb52bf56c310f8b2d3ff4725d9
- payload
- application numbers
- BLA761444
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-2d2f0b8ac88a9811d19a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- cant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 ( NCT00321464 ) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemot
- end
- 1163
- exact text
- NCT00321464
- start
- 1152
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/77/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 5959022d-c2d4-11ec-e063-6294a90a6cd6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 0d61aa3bd9ab6cae02f9d2c808748b661af448be5391e08264979bed2329a1f9
- spl effective time
- 20260818
- spl set id
- b1f0590e-f5bb-44ac-99a0-4aa4596c7e54
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-2d6bf7de1cda870687f4
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- 70159c7c-a439-4a9c-82d4-8c6da6c345eb
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 00f7bf36072d38c1304f2ed8315fbf658190b38f2095f8cf170c92b529162f0e
- payload
- application numbers
- BLA761439
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-2d6bf7de1cda870687f4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1162
- exact text
- NCT00321464
- start
- 1151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/46/spl_unclassified_section/0
- source kind
- fda_spl_label
- source record id
- 70159c7c-a439-4a9c-82d4-8c6da6c345eb
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e97b6a514f9124d9171e3a289c27829cba3fae2bf82b6d62e22a0160871461fb
- spl effective time
- 20250902
- spl set id
- a48a3a33-6b0e-4cf4-8786-8f662d6ee77b
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-631991d2925dc5e274e1
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- caa201eb-143f-4390-9788-894e1810fee8
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- a13b0acc87d9244f74c5b17d975fcbd443f189222363530a0cacbb8bc6cf1a7b
- payload
- application numbers
- BLA761424
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-631991d2925dc5e274e1
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- cant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 ( NCT00321464 ) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemot
- end
- 1163
- exact text
- NCT00321464
- start
- 1152
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/69/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- caa201eb-143f-4390-9788-894e1810fee8
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- efe95ad718893c51a3ebb4cc673d6fa2ddbf039db758cbf8c37c2d15e8fcd7a3
- spl effective time
- 20260714
- spl set id
- e15dfe74-1575-4a2a-895e-323c05613362
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-85d3eb8d1d707ef8fe58
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- 515e94c3-ab8d-4c35-8e7c-7083fd423d60
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 1a91c32dad1fa91877949dc0ff424fea7b4e358c4beca193cbb82d341372b7f0
- payload
- application numbers
- BLA761404
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-85d3eb8d1d707ef8fe58
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- cant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 ( NCT00321464 ) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemot
- end
- 1163
- exact text
- NCT00321464
- start
- 1152
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/41/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 515e94c3-ab8d-4c35-8e7c-7083fd423d60
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2efdc6cd516094b6f3670cf0c1b1486e6ed1fb5bd1f759bead892e61fec8ac39
- spl effective time
- 20260205
- spl set id
- d378622d-3a13-4918-ae18-3375cd10d270
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-a20c604090751aae0fbb
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- b34597a1-251b-4c4b-9457-c3de26d5c26e
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 83220c62b02c747b5841625801e5d44564b61d1f012a8058659714e72d899059
- payload
- application numbers
- BLA761457
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-a20c604090751aae0fbb
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1162
- exact text
- NCT00321464
- start
- 1151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/11/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b34597a1-251b-4c4b-9457-c3de26d5c26e
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e840c0fe43f992eebe6415c419771a06711845efa6311fcab59a5b5ca4695a42
- spl effective time
- 20251222
- spl set id
- f040a245-1be4-4962-a8b7-a13ee7fac707
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-a33d3c69973b2d295b86
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- payload sha256
- 7855b75dc7f5609a7b873207056c3ac7916e34015007b9440933bc0b1f7591f4
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-a33d3c69973b2d295b86
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- ody denosumab inhibits the receptor activator of nuclear factor kappa beta ligand (RANKL). A meta-analysis of three phase III trials (<a href="/clinicaltrials/NCT00321464">NCT00321464</a>, <a href="/clinicaltrials/NCT00321620">NCT00321620</a>, and <a href="/clinicaltrials/NCT00330759">NCT00330759</a>) comparing zoledronate versu
- end
- 674012
- exact text
- NCT00321464
- start
- 674001
- context exact
- inhibits the receptor activator of nuclear factor kappa beta ligand (RANKL). A meta-analysis of three phase III trials (<a href="/clinicaltrials/NCT00321464">NCT00321464</a>, <a href="/clinicaltrials/NCT00321620">NCT00321620</a>, and <a href="/clinicaltrials/NCT00330759">NCT00330759</a>) comparing zoledronate versus denosumab f
- end
- 674025
- exact text
- NCT00321464
- start
- 674014
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/29bf1e5a1d739974ed.html
- source file sha256
- 862f78faa9e4cbedc19f9ffcaeba97e029ba51b72bb3b81fc67aa8b6adf96904
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:35.419733+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 536430925e3b0008edd3fb69a869d5645bd6b6dc5c84c21ddf1b3e24f089874c
- source title
- Breast Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: April 25, 2025
- datetime
- 2025-04-25T12:00:00Z
- display
- April 25, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-a6b817e51db70127d15d
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- ccc3be04-f9b8-46d8-a1a9-0aacdb418c3b
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- b4f172fd17d28d093182f4ab8de4ca0e168f1f8622e7e9827d0c2073350b09bd
- payload
- application numbers
- BLA761404
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-a6b817e51db70127d15d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- cant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 ( NCT00321464 ) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemot
- end
- 1163
- exact text
- NCT00321464
- start
- 1152
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/74/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ccc3be04-f9b8-46d8-a1a9-0aacdb418c3b
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3a7f4960e1ef0bcc5ac213c6c2960aec2fa74229503ba15f7b7041c3bd8932c7
- spl effective time
- 20260205
- spl set id
- c5a5d750-80be-49cd-b4a6-c8a815956059
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bdfb4d6e2e40b9bebc44
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- 3ce47aaf-105d-4615-9320-1f378a9d8d84
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- 2cb5b0b8e9f3b5e1d15fabc7e3b470e1cab970cd3a68ff482cec1bb0812bc0a4
- payload
- application numbers
- BLA125320
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bdfb4d6e2e40b9bebc44
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1159
- exact text
- NCT00321464
- start
- 1148
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/27/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 3ce47aaf-105d-4615-9320-1f378a9d8d84
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 21b6b11467df323cd5f5eecbcbc71a255e3c705ca59764e28c3fdd2aa7813a43
- spl effective time
- 20260623
- spl set id
- 628f0998-1206-4001-aeee-18133aa9f3bf
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c5343480afb245e2575a
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- 019c406f-d5d0-d9d0-25c1-664d4dc4e776
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- b93e674f91305ea0486c288a46cf45e8ea0e0a8be4edf3a180a88ac94f0ea25d
- payload
- application numbers
- BLA761436
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c5343480afb245e2575a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1162
- exact text
- NCT00321464
- start
- 1151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/10/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 019c406f-d5d0-d9d0-25c1-664d4dc4e776
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 269f94d5b41d66e13f264385e5d1a24dd194b8a4bffbf55506c11c625aa3abbb
- spl effective time
- 20260327
- spl set id
- 547cb095-f7f5-f933-75ce-5e6abf2ad5bc
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e9a8b4651b82e6c03c05
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- c0ae96a3-47b7-4b70-98a2-e88074ff6f10
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- df91d206b4caebf760854aff8ff3541ff39a3f31c7ea84906eaa88cc124d0481
- payload
- application numbers
- BLA761362
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e9a8b4651b82e6c03c05
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1162
- exact text
- NCT00321464
- start
- 1151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/44/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- c0ae96a3-47b7-4b70-98a2-e88074ff6f10
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 4a85d111704de6e1ca7b3236c275b0a7a243a27971bedeaf768a4f2f63d3cc4d
- spl effective time
- 20260220
- spl set id
- 69e4890d-5dd9-42a5-aa41-ce50635eaed7
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-f0a90836dea09cbba902
- requested nct id
- NCT00321464
- primary nct id
- NCT00321464
- source kind
- fda_spl_label
- source record id
- fd3a3b73-bf8e-4538-9eee-b3d652251260
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- payload sha256
- 293c23904c5934ac1f7c26c8f3921a53df4abf74637acdee0aeb1a934184a6e1
- payload
- application numbers
- BLA761398
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-f0a90836dea09cbba902
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00321464
- occurrences
- context exact
- icant. An SRE was defined as any of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Study 20050136 (NCT00321464) enrolled 2046 patients with advanced breast cancer and bone metastasis. Randomization was stratified by a history of prior SRE (yes or no), receipt of chemoth
- end
- 1162
- exact text
- NCT00321464
- start
- 1151
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00800.json
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- source json pointer
- /results/24/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- fd3a3b73-bf8e-4538-9eee-b3d652251260
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 65a1641992a958bbf1b55ff1a9fddccfae5377bc9fca0419e903be7f90e95576
- spl effective time
- 20250331
- spl set id
- 49d25732-e05d-47e4-98cb-67df04796d4b
Preserved source evidence · Not medical advice